Latest Rare diseases Stories
In his new role, Dr.
Acceptance of Regulatory Submission Triggers $10 Million Milestone Payment to Auxilium CHESTERBROOK, Pa., July 31, 2014 /PRNewswire/ --
LEXINGTON, Mass., July 30, 2014 /PRNewswire/ -- Synageva BioPharma Corp. ("Synageva") (NASDAQ: GEVA), a biopharmaceutical
LifeScienceIndustryResearch.com adds “Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014” to its store.
ArmaGen to Receive up to Approximately $225 Million Including Initial Upfront Payment of $15 Million in Cash and Equity, an Additional Equity Investment, R&D Funding, Development and Sales Milestones,
- Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 - PLANTATION, Fla., July 22, 2014 /PRNewswire/
DUBLIN, July 18, 2014 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
Publication in Science Unveils Novel, Diverse and Separate Biological Functions That Can Be Harnessed Therapeutically to Mediate a Wide Range of Human Disease SAN DIEGO and HONG KONG,
ReportsnReports.com adds “OpportunityAnalyzer Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018” to its store.
Talc Pleurodesis Offers Several Benefits Over Video-Assisted Method of Reducing Fluid Buildup in Lungs DALLAS (PRWEB) July 10, 2014 Researchers in the
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.